Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

AVG DIRECTIONAL INDEX


Last Signal:

MEDIUM TREND


Trading: HOLD @ $23
Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.


Clinuvel Pharmaceuticals (ASX:CUV) has confirmed a strong trend is present. Clinuvel Pharmaceuticals has an ATR(14) of 0.796, a DX of 21.46 & an ADX(14) of 28.9



The Average Directional Index (ADX) Minus Directional Indicator (-DI) and Plus Directional Indicator (+DI) represent a group of directional movement indicators that form a trading system developed by Welles Wilder.

Calculation: Average Directional Movement Index (ADX):
Trend Strength ;
1) 0-25 = Absent or Weak Trend;
2) 25-50 = Strong Trend;
3) 50-75 = Very Strong Trend;
4) 75-100 Extremely Strong Trend;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Average Directional Index

Download button icon Download
Company Close Change (%) Volume Value Signal
MVP Medical Developments 3.91 7.4 111,742 -23.31 NEUTRAL
NEC Nine Entertainment 1.49 7.2 17,312,234 16.95 NEUTRAL
BOC Bougainville Copper 0.15 7.1 5,000 16.03 NEUTRAL
ISU Iselect 0.8 6.7 159,619 -18.49 NEUTRAL
JIN Jin 9.83 6.3 1,252,407 17.82 NEUTRAL
FDV Frontier Digital Ventures 0.51 6.3 308,940 -24.96 NEUTRAL
ONE Oneview Healthcare 0.48 5.6 567 21.43 NEUTRAL
CAR Carsales 12.02 5.6 1,590,263 -22.4 NEUTRAL
MOY Millennium Minerals 0.21 5.1 741,093 23.21 NEUTRAL
DNK Danakali 0.76 4.9 425,514 -21.05 NEUTRAL
back to top